KR890001584A - Gh-분비호르몬, 콜린성 효능제 및 경우에 따라 담즙산염을 함유하는 비내 투여용 약제 조성물 - Google Patents
Gh-분비호르몬, 콜린성 효능제 및 경우에 따라 담즙산염을 함유하는 비내 투여용 약제 조성물 Download PDFInfo
- Publication number
- KR890001584A KR890001584A KR1019880009436A KR880009436A KR890001584A KR 890001584 A KR890001584 A KR 890001584A KR 1019880009436 A KR1019880009436 A KR 1019880009436A KR 880009436 A KR880009436 A KR 880009436A KR 890001584 A KR890001584 A KR 890001584A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- composition
- nasal
- ghrh
- acid
- Prior art date
Links
- 239000003833 bile salt Substances 0.000 title claims 9
- 239000000064 cholinergic agonist Substances 0.000 title claims 9
- 229940093761 bile salts Drugs 0.000 title claims 7
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000003248 secreting effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 10
- 102100022831 Somatoliberin Human genes 0.000 claims 7
- 101710142969 Somatoliberin Proteins 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 claims 2
- -1 betanecol Chemical compound 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229940097496 nasal spray Drugs 0.000 claims 2
- 239000007922 nasal spray Substances 0.000 claims 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 claims 1
- 108010007979 Glycocholic Acid Proteins 0.000 claims 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 claims 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 claims 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 claims 1
- 229960000451 ambenonium Drugs 0.000 claims 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- RWZVPVOZTJJMNU-UHFFFAOYSA-N demarcarium Chemical compound C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 RWZVPVOZTJJMNU-UHFFFAOYSA-N 0.000 claims 1
- 229960004656 demecarium Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical group C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 1
- 229940099347 glycocholic acid Drugs 0.000 claims 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 150000008282 halocarbons Chemical class 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 claims 1
- 229960002329 methacholine Drugs 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 229940100652 nasal gel Drugs 0.000 claims 1
- 229940100657 nasal ointment Drugs 0.000 claims 1
- 229940052404 nasal powder Drugs 0.000 claims 1
- 229940100656 nasal solution Drugs 0.000 claims 1
- 229960002362 neostigmine Drugs 0.000 claims 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960001416 pilocarpine Drugs 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
- 229960001661 ursodiol Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 및 제2도는 어린이를 대상으로한 임상시험(혈중 GH함량) 결과의 다이아그램,
제3 및 제4도는 성인을 대상으로한 임상시험(혈중 GH함량)결과의 다이아그램.
Claims (11)
- 비내 투여를 위해 약제학적으로 허용되는 무독성 부형제와 함께 치료유효량의 GHRH, 콜린성 효능제 및 경우에 따라 담즙 산염을 함유함을 특징으로 하는, 성장장애의 치료 및 뇌하수체 기능의 진단에 적합한 비내 투여용 약제 조성물.
- 제1항에 있어서, 비내 산제, 비내 현탁액, 비내 연고, 비내 크림, 비내 용액, 비내 겔, 서방성 겔, 비내 점적제, 비내 분무제, 또는 비내 스프레이의 형태임을 특징으로 하는 조성물.
- 제1항에 있어서, 콜린성 효능제가 메타콜린, 카바콜, 베타네콜, 아레콜린, 필로카핀, 무스카린, 아시클리딘, 옥소트레모린, 피조스티그민, 네오스티그민, 에드로포늄, 피리도스티그민, 데메카륨, 암베노늄 및 이들의 염임을 특징으로 하는 조성물.
- 제1항에 있어서, 담즙산염이 글리코콜산, 글리코케노데옥시콜산, 타우로콜산, 타우로케노데옥시콜산, 데옥시콜산, 케노데옥시콜산, 우르소데옥시콜산, 또는 글리코데옥시콜산의 알칼리염을 특징으로 하는 조성물.
- 제1항에 있어서, 등장성임을 특징으로 하는 조성물.
- 제1항에 있어서, 물을 기제로 하며 GHRH 0.01내지 0.75중량%, 콜린성 효능제 0.15내지 7.5중량%, 및 경우에 따라 담즙산염 0.5내지 5중량%를 함유하는 조성물.
- 제1항에 있어서, 할로겐화 탄화수소 추진제를 기제로 하며 GHRH 0.01내지 1.0중량%, 콜린성 효능제 0.3내지 4.0중량 및 경우에 따라 담즙산염 0.5 내지 5중량%를 함유하는 조성물.
- 제1항에 있어서, 겔화된 매트릭스를 기제로 하며, GHRH 0.2 내지 1.5중량%, 콜린성 효능제 1.5 내지 7.5중량%인 경우에 따라 담즙산염 0.5내지 5중량%를 함유하는 조성물.
- 제1항에 있어서, 오일/물 또는 물/오일 유제 형태이며, GHRH 0.2내지 1.5중량%, 콜린성 효능제 1.5내지 7.5중량% 및 경우에 따라 담즙산염 0.5 내지 5중량%를 함유하는 조성물.
- 제1항에 있어서, GHRH 0.4내지 3중량%, 콜린성 효능제 3내지 15중량% 및 경우에 따라 담즙산염 0.5내지 5중량%를 함유하며 산제형태의 조성물.
- 제1항내지 10항중 어느 한 항에 있어서, GHRH 3내지 60μg/체중kg, 콜린성 효능제 20 내지 100μg/체중 kg 및 경우에 따라 담즙산염 10 내지 50μg/체중 kg 으로 구성된 용량으로 투여됨을 특징으로 하는 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT21513A/87 | 1987-07-30 | ||
| IT21513/87A IT1222395B (it) | 1987-07-30 | 1987-07-30 | Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR890001584A true KR890001584A (ko) | 1989-03-27 |
Family
ID=11182925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880009436A KR890001584A (ko) | 1987-07-30 | 1988-07-27 | Gh-분비호르몬, 콜린성 효능제 및 경우에 따라 담즙산염을 함유하는 비내 투여용 약제 조성물 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5010056A (ko) |
| EP (1) | EP0301392B1 (ko) |
| JP (1) | JPS6450823A (ko) |
| KR (1) | KR890001584A (ko) |
| AT (1) | ATE76753T1 (ko) |
| AU (1) | AU618547B2 (ko) |
| DK (1) | DK393188A (ko) |
| IT (1) | IT1222395B (ko) |
| NO (1) | NO883200L (ko) |
| NZ (1) | NZ225546A (ko) |
| PH (1) | PH26712A (ko) |
| ZA (1) | ZA885417B (ko) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0383931A (ja) * | 1989-08-29 | 1991-04-09 | Sumitomo Pharmaceut Co Ltd | 低刺激性ｇｒｆ経鼻投与製剤 |
| EP0432431B1 (en) * | 1989-11-16 | 1993-06-16 | PHIDEA S.p.A. | Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient |
| US5502067A (en) * | 1994-02-04 | 1996-03-26 | Morgan; Julia A. | Treating apneahypopnea/snoring in humans |
| US5500205A (en) * | 1994-02-23 | 1996-03-19 | Enviro Pac International, L.I.C. | Lachrymator aerosol formulations |
| US5861431A (en) * | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
| AUPN801296A0 (en) | 1996-02-12 | 1996-03-07 | Csl Limited | Stabilised growth hormone formulation and method of preparation thereof |
| CA2281755C (en) * | 1997-02-24 | 2006-11-07 | Michael Albert Kamm | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| US8048875B1 (en) | 1997-02-24 | 2011-11-01 | S.L.A. Pharma Ag | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| ATE289825T1 (de) * | 1999-04-21 | 2005-03-15 | 1355540 Ontario Inc | Methacoline oder histamine formulierungen zur feststellung von asthma |
| AU5072000A (en) * | 1999-06-02 | 2000-12-28 | Hexal Ag | Pharmaceutical composition for nasally administering water-soluble active substances |
| AU1261501A (en) * | 1999-12-06 | 2001-06-18 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
| JP3498041B2 (ja) * | 2000-05-29 | 2004-02-16 | 科研製薬株式会社 | プラルモレリン含有点鼻用製剤 |
| US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| JP6556129B2 (ja) * | 2013-08-01 | 2019-08-07 | アメリカ合衆国 | ファルネソイドｘ受容体の阻害剤及び医薬としての使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3371281D1 (en) * | 1982-12-10 | 1987-06-11 | Syntex Inc | Lhrh preparations for intranasal administration |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| IT1169873B (it) * | 1983-10-21 | 1987-06-03 | Prodotti Formenti Srl | Composizione farmaceutica ad attivita' sistemica anticolinesterasica, agonista-colinergica ed antimuscarinica |
| US4818531A (en) * | 1985-02-06 | 1989-04-04 | Eli Lilly And Company | Growth hormone and thyroid hormone |
| JPS62126135A (ja) * | 1985-11-25 | 1987-06-08 | Sumitomo Pharmaceut Co Ltd | 経鼻投与用ｇｒｆ製剤 |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US4880778A (en) * | 1986-05-12 | 1989-11-14 | Eastman Kodak Company | Combinations having synergistic growth hormone releasing activity and methods for use thereof |
-
1987
- 1987-07-30 IT IT21513/87A patent/IT1222395B/it active
-
1988
- 1988-07-14 DK DK393188A patent/DK393188A/da not_active Application Discontinuation
- 1988-07-19 NO NO88883200A patent/NO883200L/no unknown
- 1988-07-20 EP EP88111657A patent/EP0301392B1/en not_active Expired - Lifetime
- 1988-07-20 AT AT88111657T patent/ATE76753T1/de active
- 1988-07-21 PH PH37251A patent/PH26712A/en unknown
- 1988-07-25 US US07/223,378 patent/US5010056A/en not_active Expired - Fee Related
- 1988-07-25 ZA ZA885417A patent/ZA885417B/xx unknown
- 1988-07-25 NZ NZ225546A patent/NZ225546A/en unknown
- 1988-07-26 AU AU20051/88A patent/AU618547B2/en not_active Ceased
- 1988-07-27 KR KR1019880009436A patent/KR890001584A/ko not_active Application Discontinuation
- 1988-07-28 JP JP63187052A patent/JPS6450823A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US5010056A (en) | 1991-04-23 |
| IT8721513A0 (it) | 1987-07-30 |
| DK393188A (da) | 1989-01-31 |
| IT1222395B (it) | 1990-09-05 |
| NO883200D0 (no) | 1988-07-19 |
| AU618547B2 (en) | 1992-01-02 |
| EP0301392A1 (en) | 1989-02-01 |
| AU2005188A (en) | 1989-02-02 |
| EP0301392B1 (en) | 1992-06-03 |
| DK393188D0 (da) | 1988-07-14 |
| ATE76753T1 (de) | 1992-06-15 |
| NO883200L (no) | 1989-01-31 |
| ZA885417B (en) | 1989-06-28 |
| NZ225546A (en) | 1990-12-21 |
| JPS6450823A (en) | 1989-02-27 |
| PH26712A (en) | 1992-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890001584A (ko) | Gh-분비호르몬, 콜린성 효능제 및 경우에 따라 담즙산염을 함유하는 비내 투여용 약제 조성물 | |
| EP0041772B1 (en) | Fat emulsion containing a steroid | |
| US4434159A (en) | Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom | |
| US5183802A (en) | Pharmaceutical compositions for intranasal administration of calcitonin | |
| AU7643591A (en) | A pharmaceutical preparation | |
| DE3480903D1 (de) | Pharmazeutische zusammensetzungen mit gehalt an insulin. | |
| US5376365A (en) | Method of the treatment of dry nose syndrome | |
| KR950031069A (ko) | 골손실의 억제 및 혈청 콜레스테롤의 강하 방법 | |
| KR890700036A (ko) | 비내 투여용 제제 및 그 제조방법 | |
| KR910005885B1 (ko) | 염화리소짐 및 글리치르히진산 디칼륨 함유 수용액제제 | |
| US5281580A (en) | Calcitonin-containing emulsion for nasal administration | |
| JPH092944A (ja) | 眼用医薬組成物及びその投与方法 | |
| FR2712807B1 (fr) | Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale . | |
| KR960030948A (ko) | 비강투여용 비무기 식염용액 | |
| DE4201903B4 (de) | Pharmazeutische Verwendung von Boswelliasäuren | |
| JPH0228121A (ja) | 経粘膜吸収促進剤及びこれを用いた経鼻投与剤 | |
| US3966962A (en) | Triacetin solutions of PGE-type compounds | |
| JPH07196516A (ja) | 痔疾患治療剤 | |
| HU900591D0 (en) | Regulated agent-dissolving safety system and process of it's preparation | |
| JPS58131956A (ja) | 新規アミノ酸誘導体の製法 | |
| KR940005276A (ko) | 1α, 25-디히드록시-22(E)-데히드로-비타민 D₃로 이루어지는 골다공증 치료용 제약 조성물 | |
| JP2905210B2 (ja) | 経皮、経粘膜吸収促進剤および経皮、経粘膜製剤 | |
| WO1993017674A1 (en) | Topical use of local anaesthetic agents for rheumatoid arthritis as well as a pharmaceutical preparation and a method for the treatment thereof | |
| IE51737B1 (en) | Topical formulations of 3-deazaadenosine | |
| US5654335A (en) | Topical use of ethyl ethacrynate for glaucoma treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |